Applications of chemogenomic library screening in drug discovery

被引:0
|
作者
Lyn H. Jones
Mark E. Bunnage
机构
[1] Medicine Design,
[2] Pfizer,undefined
[3] Present address: Vertex Pharmaceuticals,undefined
[4] 50 Northern Avenue,undefined
[5] Boston,undefined
[6] Massachusetts 02210,undefined
[7] USA.,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
A chemogenomic library is a collection of well-defined pharmacological agents. A hit from such a set in a phenotypic screen suggests that the annotated target or targets of the probe molecules are involved in the phenotypic perturbation.The creation and utility of a number of chemogenomic libraries have been described, by academia and industry, and some are commercially available.Chemogenomic screening has the potential to expedite the conversion of phenotypic screening projects into target-based drug discovery approaches. Other applications include drug repositioning, predictive toxicology and the discovery of novel pharmacological modalities.Target identification from phenotypic screening can benefit from the integration of small-molecule chemogenomics with genetic approaches, such as RNA-mediated interference and CRISPR–Cas9.Current limitations of chemogenomic screening include small-molecule polypharmacology, misannotation of biological activity and false-positive results (deriving from compound fluorescence or luciferase reporter binding) for example, although opportunities to overcome these issues, particularly through the incorporation of computational techniques, are emerging.'Open innovation' and collaborative ventures across academia and industry are required to create and assemble the best pharmacological probes for chemogenomic libraries.
引用
收藏
页码:285 / 296
页数:11
相关论文
共 50 条
  • [1] Applications of chemogenomic library screening in drug discovery
    Jones, Lyn H.
    Bunnage, Mark E.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (04) : 285 - 296
  • [2] Chemogenomic approaches to drug discovery - Commentary
    Caron, PR
    Mullican, MD
    Mashal, RD
    Wilson, KP
    Su, MS
    Murcko, MA
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2001, 5 (04) : 464 - 470
  • [3] Applications of SHAPES screening in drug discovery
    Lepre, CA
    Peng, J
    Fejzo, J
    Abdul-Manan, N
    Pocas, J
    Jacobs, M
    Xie, XL
    Moore, JM
    [J]. COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2002, 5 (08) : 583 - 590
  • [4] Chemogenomic Approaches for Revealing Drug Target Interactions in Drug Discovery
    Bhargava, Harshita
    Sharma, Amita
    Suravajhala, Prashanth
    [J]. CURRENT GENOMICS, 2021, 22 (05) : 328 - 338
  • [5] Thematic Analysis™: A Chemogenomic Approach to GPCR Drug Discovery
    Crossley, Roger
    Macritchie, Jacqueline Anne
    Slater, Martin John
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (15) : 1925 - 1943
  • [6] A chemogenomic approach to drug discovery: focus on cardiovascular diseases
    Cases, Montserrat
    Mestres, Jordi
    [J]. DRUG DISCOVERY TODAY, 2009, 14 (9-10) : 479 - 485
  • [7] A Chemogenomic Analysis of Ionization Constants-Implications for Drug Discovery
    Manallack, David T.
    Prankerd, Richard J.
    Nassta, Gemma C.
    Ursu, Oleg
    Oprea, Tudor I.
    Chalmers, David K.
    [J]. CHEMMEDCHEM, 2013, 8 (02) : 242 - 255
  • [8] Drug discovery in the library
    Nicholls, H
    [J]. SCIENTIST, 2004, 18 (19): : 45 - 46
  • [9] Screening applications in drug discovery based on microfluidic technology
    Eribol, P.
    Uguz, A. K.
    Ulgen, K. O.
    [J]. BIOMICROFLUIDICS, 2016, 10 (01):
  • [10] Applications of NMR SHAPES screening in drug discovery.
    Moore, JM
    Fejzo, J
    Lepre, CA
    Peng, JW
    Abdul-Manan, N
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U38 - U38